Physician profile
Michael Stanik
NPI 1609812247
$458.95
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $15.74 · 2021: $73.64 · 2022: $94.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.90 | 2019 | |
| Urovant Sciences INC | $55.04 | 2021-2022 | |
| Boston Scientific Corporation | $49.77 | 2019-2022 | |
| Coloplast Corp | $49.39 | 2019-2021 | |
| Janssen Biotech, INC. | $42.73 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $41.63 | 2019 | |
| Abbvie INC. | $41.34 | 2022 | |
| Myovant Sciences INC. | $22.56 | 2021 | |
| 180 Medical, INC. | $15.74 | 2020 | |
| Astellas Pharma US INC | $14.75 | 2019 | |
| Rochester Medical Corporation | $14.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stanik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.